75,053 Shares in Omeros Corporation $OMER Bought by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 75,053 Omeros shares worth approximately $714,000, representing about 0.10% of the company. Institutional investors collectively own 48.79% of Omeros.
• Omeros reported quarterly EPS of $0.02, beating the consensus estimate of a $0.27 loss, while revenue of $28.53 million exceeded expectations of $12.69 million.
• OMER traded at $18.79, near its 12-month high of $19.65. Analysts have a consensus “Moderate Buy” rating and a $38.00 target price, although insiders sold 45,906 shares worth $850,455 over the past 90 days.

Deutsche Bank AG bought a new stake in shares of Omeros Corporation (NASDAQ:OMER - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 75,053 shares of the biopharmaceutical company's stock, valued at approximately $714,000. Deutsche Bank AG owned approximately 0.10% of Omeros as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. State of Wyoming bought a new position in shares of Omeros in the fourth quarter worth about $25,000. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros in the 2nd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Omeros in the 4th quarter worth approximately $33,000. Assetmark Inc. bought a new stake in Omeros during the 1st quarter worth approximately $38,000. Finally, Tower Research Capital LLC TRC raised its stake in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 11,971 shares during the period. Institutional investors own 48.79% of the company's stock.

Omeros Trading Up 1.0%

NASDAQ:OMER opened at $18.79 on Tuesday. The business's 50-day moving average is $12.81 and its 200 day moving average is $12.08. Omeros Corporation has a 12 month low of $3.94 and a 12 month high of $19.65. The company has a market capitalization of $1.36 billion, a P/E ratio of 14.68 and a beta of 2.54.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts' expectations of $12.69 million. On average, research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on OMER. HC Wainwright restated a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings raised Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Finally, Zacks Research cut Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Omeros has an average rating of "Moderate Buy" and a consensus target price of $38.00.

Insider Activity

In other news, Director Thomas J. Cable sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total value of $276,750.00. Following the sale, the director directly owned 35,067 shares in the company, valued at approximately $646,986.15. This represents a 29.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Arnold C. Hanish sold 10,000 shares of Omeros stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the director owned 5,000 shares of the company's stock, valued at approximately $94,750. This trade represents a 66.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 45,906 shares of company stock valued at $850,455 in the last ninety days. Insiders own 10.50% of the company's stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.